bluebird bio re-evaluates gene therapy strategy in ‘untenable’ European market
US biotech company says European payers have ‘not yet evolved their approach to gene therapy’
Read More
Tag: European market
- HUTCHMED begins global trial of novel attc therapy hmpl‑a580 in solid tumours
- Theolytics awarded €8 million Horizon Europe grant to fund ovarian cancer study
- AI system aims to uncover Alzheimer’s earlier and take on diagnostic delays
- Quell launches chill phase 1/2 trial for novel cartreg therapy
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
